| 14219-00-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• CAS: 14219-00-2
• 化学式: C7H7KNO
• 分子量: 160.23
• InChiKey: SPTNXCCSKRKUHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] SUBSTITUTED ARYL AMIDES<br/>[FR] ARYLAMIDES SUBSTITUEE
  申请人：MERCK & CO INC

  公开号：WO2003087037A1

  公开（公告）日：2003-10-23

  Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  结构式（I）的新化合物是大麻素-1（CB1）受体的拮抗剂和/或逆向激动剂，并且在治疗、预防和抑制由CB1受体介导的疾病方面具有用途。本发明的化合物可作为精神药物用于治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎性疾病（包括多发性硬化和吉兰-巴雷综合征）以及病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。这些化合物还可用于治疗物质滥用障碍、肥胖症或进食障碍的治疗，以及哮喘、便秘、慢性肠假性梗阻和肝硬化的治疗。
• METHOD FOR PRODUCING AMINO ACID DERIVATIVES
  申请人：API CORPORATION

  公开号：US20210403427A1

  公开（公告）日：2021-12-30

  The present invention aims to provide a method for producing a (2S,5R)-5-(protected oxyamino)-piperidine-2-carboxylic acid derivative at a low cost that can be performed under mild reaction conditions not requiring a facility at an extremely low temperature, is safer, can control the quality of the desired product with ease, and shows good workability in the site of production. A method for producing a compound represented by the formula (2): wherein PG 1 is an amino-protecting group, PG 2 is an amino-protecting group, PG 3 is a hydroxyl-protecting group, LG is a leaving group, and R is a hydrocarbon group having 1-8 carbon atoms and optionally having substituent(s), including a step of reacting a compound represented by the formula (1): wherein each symbol is as defined above, with a hydroxylamine derivative represented by the formula PG 2 NHOPG 3 wherein each symbol is as defined above, in the presence of a base in a solvent.

  本发明旨在提供一种低成本的方法，用于在温和反应条件下生产(2S,5R)-5-(保护氧氨基)-哌啶-2-羧酸衍生物，不需要极低温度设施，更安全，并且可以轻松控制所需产品的质量，在生产现场具有良好的可操作性。该方法包括以下步骤：与公式（1）所表示的化合物在溶剂中反应，其中PG1是氨基保护基，PG2是氨基保护基，PG3是羟基保护基，LG是离去基团，R是具有1-8个碳原子的烃基，并且可选地具有取代基，与公式PG2NHOPG3所表示的羟胺衍生物在碱的存在下反应。
• Substituted aryl amides
  申请人：Hagmann K. William

  公开号：US20050154202A1

  公开（公告）日：2005-07-14

  Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  结构式（I）的新化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗、预防和抑制由CB1受体介导的疾病。本发明的化合物可用作精神药物，用于治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎症性疾病，包括多发性硬化和格林-巴利综合征以及病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。这些化合物还可用于治疗物质滥用障碍、肥胖或进食障碍，以及哮喘、便秘、慢性肠假性梗阻和肝硬化的治疗。
• Process for producing alpha-olefin oligomers
  申请人：MITSUBISHI CHEMICAL CORPORATION

  公开号：EP0706983A1

  公开（公告）日：1996-04-17

  A process for preparing an α-olefin oligomer which comprises oligomerizing an α-olefin in a solvent in the presence of a chromium-based catalyst system comprising a combination of at least a chromium compound, an amine or metal amide, an alkylaluminium compound, and a non-coordinating Lewis acid-containing compound of formula (6) or (7): wherein M¹ and M² are each an element selected from groups IIIB, IVB, VB and VIB of the periodic table; R¹ to R⁷ are each independently an organic group, an inorganic group or an anionic atom; and [L]⁺ is a cation containing an element selected from groups IA, VIIA, VIII, IB and IIIB-VIB of the periodic table.

  一种制备α-烯烃低聚物的工艺，包括在溶剂中，在铬基催化剂体系存在下，使α-烯烃低聚，该催化剂体系至少由铬化合物、胺或金属酰胺、烷基铝化合物和式(6)或式(7)的非配位含路易斯酸化合物组合而成： 其中 M¹ 和 M² 各为选自元素周期表中 IIIB、IVB、VB 和 VIB 族的元素；R¹ 至 R⁷ 各独立地为有机基团、无机基团或阴离子原子；[L]⁺ 为含有选自元素周期表中 IA、VIIA、VIII、IB 和 IIIB-VIB 族的元素的阳离子。
• Liquid crystal material and liquid crystal display
  申请人：——

  公开号：US20020028305A1

  公开（公告）日：2002-03-07

  A dissociating substance and its salt are added to a liquid crystal to keep the amount of ions included in the liquid crystal constant under temperature variation and to prevent alignment disorder in the liquid crystal due to static electricity and unevenness or spots due to excessive ion accumulation, leading to improved reliability.

  在液晶中加入离解物质及其盐，可使液晶中的离子数量在温度变化时保持恒定，并防止液晶中因静电导致的排列紊乱以及因离子积累过多导致的不平整或斑点，从而提高可靠性。